The objective of the study is to compare effectiveness various systemic therapies in 3rd and subsequent lines therapy metastatic colon cancer. Material Methods . Retrospective multicenter collected data from 2 clinics Russian Federation. We considered overall survival (OS) as main criterion effectiveness. Progression-free (PFS) was additional criterion. performed a single- multifactorial analys...

The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells. In liver, colorectal, lung, breast, kidney, and brain cancer cells, at clinically achievable doses, sorafenib/regorafenib and the PI3K inhibitor ace...

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafen...

Locoregional therapy is the primary treatment for hepatocellular carcinoma (HCC). Sorafenib was approved as a first-line systemic therapy for advanced HCC with associated extrahepatic spread and/or vascular invasion in 2007. However, there are several limitations associated with sorafenib therapy. To overcome these problems, various clinical trials have been conducted to develop additional mole...

Rechallenge with anti-epidermal growth factor drugs represents a promising therapy in patients refractory RAS wild type (WT) metastatic colorectal cancer (mCRC). The randomized phase 2 VELO trial showed that addition of panitumumab to trifluridine/tipiracil significantly improves progression free survival (PFS) as compared third-line therapy. With longer follow-up, final overall results and pos...